<DOC>
	<DOCNO>NCT02242409</DOCNO>
	<brief_summary>A Phase II trial gemcitabine plus nab-paclitaxel second line set</brief_summary>
	<brief_title>Study Gemcitabine Abraxane Pancreas Cancer</brief_title>
	<detailed_description>This open label Phase II study evaluate clinical activity combination gemcitabine nab-paclitaxel ( abraxane ) second line treatment patient metastatic pancreatic cancer receive non-gemcitabine-based chemotherapy first line set . All patient receive drug Days 1 , 8 , 15 every 28 day . The hypothesis combination 4-month progression free survival 70 % high .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm metastatic adenocarcinoma pancreas Progression first line nongemcitabine base therapy metastatic relapse disease Radiographically measurable evaluable disease Age &gt; /= 18 year ECOG performance status 02 Adequate hepatic , bone marrow renal function Prior gemcitabinebased chemotherapy first line set No active severe infection , know chronic infection HIV hepatitis B virus No cardiovascular disease problem include unstable angina , therapy lifethreatening ventricular arrhythmia , myocardial infarction , stroke , congestive heart failure within last 6 month No woman pregnant breastfeeding , woman childbearing potential without use dual form contraception Patients know CNS metastases History allergic reaction attribute compound similar chemical biologic composition gemcitabine nabpaclitaxel Anticipated patient survival 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastatic pancreatic cancer</keyword>
	<keyword>Second Line treatment</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Nab-paclitaxel</keyword>
</DOC>